A scan that makes prostate cancer cells “glow” could halve the number of men needing invasive biopsies, research suggests.
Australian scientists say it could also help reduce the risk of overdiagnosis by determining which cancers are low-risk and will never cause harm. The post New state-of-the-art test identifies ...
An imaging test could safely halve the number of people who need a biopsy for suspected prostate cancer following ...
Researchers in Denmark conducted a prospective single-centre study including 160 patients with newly diagnosed high-risk prostate cancer between 2021 and 2024. All the participants first underwent an ...
A world-first trial of Australian men has confirmed a specialised scan can accurately “light up” prostate cancer, saving ...
Approximately 20% to 40% of men who have surgery for localized prostate cancer will see the cancer return within 10 years, often first detected by a rising PSA blood test. When this happens, doctors ...
Visual Abstract. Overall survival for patients treated with salvage radiotherapy: real world data from an entire country. A patient with biochemical recurrence after radical prostatectomy and no ...
FDA approves Pylarify TruVu, a new prostate cancer PET imaging agent designed to expand access and improve detection of recurrent or metastatic disease.
The 2026 European Association of Urology (EAU) annual meeting featured a plenary prostate cancer session and a presentation by Dr. Jozefina Casuscelli discussing the optimal management of de-novo ...
More than 100,000 future cancer cases were projected to result from the 93 million CT examinations performed in 2023, according to a study published April 14 in JAMA Internal Medicine. Low-dose CT ...
Private companies are capitalizing on this quest for information. Grail’s Galleri blood test screens for more than 50 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results